The Rechallenge of ADCs in MBC Patients

A Multicenter, Real-world Study of the Efficacy and Safety of Antibody-drug Conjugates (ADCs) Rechallenge in Patients with Prior Exposure to ADCs Metastatic Breast Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05571618

Enrollment

100

Registered

2022-10-07

Start date

2022-09-01

Completion date

2025-03-01

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Antibody-drug conjugates, Metastatic Breast Cancer

Brief summary

To investigate the efficacy and safety of ADC rechallenge

Interventions

DRUGADC

Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed).

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age \> 18 years old. * Diagnosed with Metastatic Breast Cancer. * Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed). * Patients plan to or have received ADCs for the second or more time. * Complete medical history was available.

Exclusion criteria

* Medical history was incomplete

Design outcomes

Primary

Measure	Time frame	Description
PFS	6 weeks	Progression free survival

Secondary

Measure	Time frame	Description
ORR	6 weeks	Objective Response Rate
CBR	6 weeks	Clinical Benefit Rate
DoR	6 weeks	Duration of Response
Adverse events	6 weeks	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
OS	6 weeks	Overall Survival

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026